In vitro Activity of Acyclic Nucleoside Phosphonate Derivatives against Feline Immunodeficiency Virus in Crandell Feline Kidney Cells and Feline Peripheral Blood Lymphocytes
Free accessResearch articleFirst published online February, 1994
In vitro Activity of Acyclic Nucleoside Phosphonate Derivatives against Feline Immunodeficiency Virus in Crandell Feline Kidney Cells and Feline Peripheral Blood Lymphocytes
Several novel fluorinated acyclic nucleoside phosphonates [i.e. 9-(3-fluoro-2-phosphonylmethoxy propyl)adenine (FPMPA) and 9-(3-fluoro-2-phosphonylmethoxypropyl)-2,6-diaminopurine (FPMPDAP)] were evaluated for their inhibitory effect against feline immunodeficiency virus (FIV) replication in Crandell feline kidney (CrFK) cells and feline peripheral blood lymphocytes (PBL) in vitro. Whereas 3-azido-3-deoxythymidine (AZT) was not able to achieve complete suppression of viral antigen expression and reverse transcriptase activity in the FIV-infected cell culture supernatants at 25 μM, FPMPA, FPMPDAP, and the 9-(2-phosphonylmethoxyethyl)purine derivatives PMEA and PMEDAP fully protected FIV-infected cells at μM. Both FPMPA and FPMPDAP were endowed with a higher antiviral potency and/or therapeutic selectivity than PMEA and PMEDAP in inhibiting FIV infection, mainly due to a markedly lower toxicity for the cell cultures.
References
1.
BabaM.TanakaH.De ClercqE.PauwelsR.BalzariniJ.ScholsD.NakashimaH.PernoC.-F.WalkerR.T., and MiyasakaT. (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun165: 1375–1381.
2.
BalzariniJ.KangG.-J.DalaiM.HerdewijnP.De ClercqE.BroderS., and JohnsD.G. (1987) The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonu-cleosides: a comparison with their parental 2′,3′-dideoxyribo-nucleosides. Mol Pharmacol32: 162–167.
3.
BalzariniJ.BabaM.PauwelsR.HerdewijnP., and De ClercqE. (1988) Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem Pharmacol37: 2847–2856.
4.
BalzariniJ.NaesensL.HerdewijnP.RosenbergI.HolyA.PauwelsR.BabaM.JohnsD.G., and De ClercqE. (1989a) Marked in vivo antiretrovirus activity of 9-(2-phosphonylme-thoxyethyljadenine, a selective antihuman immunodeficiency virus agent. Proc Natl Acad Sci USA86: 332–336.
5.
BalzariniJ.van AerschotA.PauwelsR.BabaM.ScholsD.HerdewijnP., and De ClercqE. (1989b) 5-Halogeno-3′-fluoro-2′,3′-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3′-fluoro-2′,3′-dideoxy-5-chlorouridine. Mol Pharmacol35: 571–577.
6.
BalzariniJ.NaesensL., and De ClercqE. (1990) Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int J Cancer46: 337–340.
7.
BalzariniJ.HolyA.JindrichJ.DvorakovaH.HaoZ.SnoeckR.HerdewijnP.JohnsD.G., and De ClercqE. (1991a) 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci USA88: 4961–4965.
8.
BalzariniJ.NaesensL.SlachmuyldersJ.NiphuisH.RosenbergI.HolyA.SchellekensH., and De ClercqE. (1991b) 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS5: 21–28.
9.
BalzariniJ.PernoC.-F.ScholsD., and De ClercqE. (1991c) Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun178: 329–335.
10.
BalzariniJ.Pérez-PérezM.-J.San-FélixA.ScholsD.PernoC.-F.VandammeA.-M.CamarasaM.-J., and De ClercqE. (1992a) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci USA89: 4392–4396.
11.
BalzariniJ.HolyA.JindrichJ.NaesensL.SnoeckR.ScholsD., and De ClercqE. (1993) Differential antiherpesvirus antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in in vivo antiretrovirus activities of (fl)-9-(2-phosphonomethoxy-propyl)-2,6-diaminopurine. Antimicrob Agents Chemother37: 322–338.
12.
De ClercqE. (1991) Broad-spectrum anti-DNA virus and antiretrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem Pharmacol42: 963–972.
13.
De ClercqE.HolyA., and RosenbergI. (1989) Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother33: 185–191.
14.
EgberinkH.BorstM.NiphuisH.BalzariniJ.NeuH.SchellekensH.De ClercqE.HorzinekM., and KoolenM. (1990) Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA87: 3087–3091.
15.
FauldsD., and BrogdenR.N. (1992) Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. DrugsA4: 94–116.
16.
GoldmanM.E.NumbergJ.H.O'BrienJ.A.QuinteroJ.C.SchleifW.A.FreundK.F.GaulS.L.SaariW.S.WaiJ.S.HoffmanJ.M.AndersonP.S.HupeD.J.EminiE.A., and SternA.M. (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA88: 6863–6867.
17.
HarbourD.A.WilliamsP.D.Gruyffydd-JonesT.J.BurbridgeJ., and PearsonG.R. (1988) Isolation of a T-lymphotropic lentivirus from a persistently leucopenic domestic cat. Vet Rec122: 84–86.
18.
HartmannK., and HinzeK. (1991) Epidemiologie und Klinik der FIV-lnfektion in Bayern. Tierärtzl Prax19: 545–551.
19.
HartmannK.DonathA.BeerB.EgberinkH.F.HorzinekM.C.LutzH.Hoffmann-FezerG.ThumI., and ThefeldS. (1992) Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol35: 167–175.
20.
HerdewijnP.BalzariniJ.De ClercqE.PauwelsR.BabaM.BroderS., and VanderhaegheH. (1987) 3′-Substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem30: 1270–1278.
21.
HolyA., and RosenbergI. (1987) Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. Collect Czech Chem Commun52: 2801–2809.
22.
HolyA.VotrubaI.MertaA.CernyJ.VeselyJ.VlachJ.SedivaK.RosenbergI.OtmarM.HrebabeckyH.Trav-NicekM.VonkaV.SnoeckR., and De ClercqE. (1990) Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res13: 295–312.
23.
IshidaT.WashizuT.ToriyabeK.MotoyoshiS.TomodaI., and PetersenN.C. (1989) Feline immunodeficiency virus infection in cats of Japan. J Am Vet Med Assoc194: 221–225.
24.
KuklaM.J.BreslinH.J.PauwelsR.FeddeC.L.MirandaM.ScottM.K.SherrillR.G.RaeymaekersA.van GelderJ.AndriesK.JanssenM.A.C.De ClercqE., and JanssenP.A.J. (1991) Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin 2(1H)-one (TIBO) derivatives. J Med Chem34: 746–751.
25.
MerluzziV.J.HargraveK.D.LabadiaM.GrozingerK.SkoogM.WuJ.C.ShihC.-K.EcknerK.HattoxS.AdamsJ.RosenthalA.S.FaanesR.EcknerR.J.KoupR.A., and SullivanJ.L. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science250: 1411–1413.
26.
MitsuyaH., and BroderS. (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA83: 1911–1915.
27.
MitsuyaH.WeinholdK.J.FurmanP.A.St. ClairM.H.LehrmanS. NusinoffGalloR.C.BolognesiD.BarryD.W., and BroderS. (1985) 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA82: 7096–7100.
28.
NaesensL.BalzariniJ.RosenbergI.HolyA., and De ClercqE. (1989) 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis8: 1043–1047.
29.
NaesensL.BalzariniJ., and De ClercqE. (1991) Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res16: 53–64.
30.
NorthT.W.NorthG.T., and PedersenN.C. (1989) Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother33: 915–919.
31.
OlmstedR.A.BarnesA.K.YamamotoJ.K.HirschV.M.PurcellR.H., and JohnsonP.R. (1989a) Molecular cloning of feline immunodeficiency virus. Proc Natl Acad Sci USA86: 2448–2452.
32.
OlmstedR.A.HirschV.M.PurcellR.H., and JohnsonP.R. (1989b) Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci USA86: 8088–8092.
33.
PauwelsR.BalzariniJ.ScholsD.BabaM.DesmyterJ.RosenbergI.HolyA., and De ClercqE. (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother32: 1025–1030.
34.
PauwelsR.AndriesK.DesmyterJ.ScholsD.KuklaM.J.BreslinH.J.RaeymaeckersA.van GelderJ.WoestenborghsR.HeykantsJ.SchellekensK.JanssenM.A.C.De ClercqE., and JanssenP.A.J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature343: 470–474.
35.
PauwelsR.AndriesK.DebyserZ.van DaeleP.ScholsD.VandammeA.-M.StoffelsP.De VreeseK.WoestenborghsR.JanssenC.G.M.AnneJ.CauwenberghG.DesmyterJ.HeykantsJ.JanssenM.A.C.De ClercqE., and JanssenP.A.J. (1992) Potent and highly selective HIV-1 inhibition by a new series of α-anilino phenyl acetamide (α-APA) derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA, in press.
36.
PedersenN.C.HoE.M.BrownM.L., and YamamotoJ.K. (1987) Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science235: 790–793.
37.
PedersenN.C.YamamotoJ.K.IshidaT., and HansenH. (1989) Feline immunodeficiency virus infection. Vet Immunol Immunopathol21: 111–129.
38.
RichmanD.D.FischlM.A.GriecoM.H.GottliebM.S.VolberdingP.A.LaskinO.L.LeedomJ.M.GroopmanJ.E.MildvanD.HirschM.S.JacksonG.G.DurackD.T., Nusinoff-Lehrman, S., and the AZT Collaborative Working Group (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex; a double-blind, placebo-controlled trial. New Engl J Med317: 185–191.
39.
RomeroD.L.BussoM.TanC.-K.ReusserF.PalmerJ.R.PoppeS.M.AristoffP.A.DowneyK.M.SoA.G.ResnickL., and TarpleyW.G. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA88: 8806–8810.
40.
TalbottR.L.SpargerE.E.LovelaceK.M.FitchW.M.PedersenN.C.LuciwP.A., and ElderJ.H. (1989) Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA86: 5743–5747.
41.
YarchoanR., and BroderS. (1989) Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides. Pharmacol Therap40: 329–348.
42.
YarchoanR.PernoC.F.ThomasR.V.KleckerR.W.AllainJ.-P.WillsR.J.McAteeN.FischlM.A.DubinskyR.McNeelyM.C.MitsuyaH.PludaJ.M.LawleyT.J.LeutherM.SafaiB.CollinsJ.M.MyersC.E., and BroderS. (1988) Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lanceti: 76–81.
43.
YarchoanR.MitsuyaH.MyersC.E., and BroderS. (1989) Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. New Engl J Med321: 726–738.
